ViGeneron GmbH news

ViGeneron presents preclinical data on intravitreal gene therapy of Stargardt disease at ESGCT

Efficient transfer of larger gene via ViGeneron’s proprietary technology platforms REVeRT and vgAAV
ViGeneron advances its preclinical programs for Stargardt disease and Retinitis Pigmentosa into IND-enabling activities and clinical stage development

ViGeneron GmbH, a next-generation gene therapy company, today announced the presentation of preclinical data on its program VG801 in ABCA4-associated Stargardt disease (STGD

Jan. 28, yyyy

ViGeneron Announces Closing of Series A Financing to Drive Development of Next Generation Gene Therapy Pipeline

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.

Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms.
Round attracts two est

Jan. 28, yyyy

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

The companies agree a follow-on collaboration to evaluate ViGeneron’s adeno-associated virus vectors (vgAAVs) for delivering Daiichi Sankyo’s novel therapeutic protein to treat prevalent eye diseases

ViGeneron GmbH, a next-generation gene therapy company, today announced a follow-on collaboration w

Apr. 26, yyyy

ViGeneron signs gene therapy strategic collaboration and option agreement with Regeneron for one inherited retinal disease target

Regeneron receives access to ViGeneron’s vgAAV capsids for one inherited retinal disease target and an option for an exclusive license to develop and commercialize the gene therapy product
ViGeneron is eligible to receive upfront payment, research funding, option exercise fee, development and commercial milestone payments, plus royalties on net sales
The collaboration further validates ViGeneron’s next generation vgAAV platform and ophthalmic gene therap

Apr. 6, yyyy

ViGeneron announces research collaboration with Daiichi Sankyo to evaluate vgAAV for novel ophthalmic gene therapy

ViGeneron GmbH, a gene therapy company, today announced a research collaboration to utilize its novel engineered adeno-associated virus (vgAAV) vectors with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”), for delivering a novel therapeutic protein to address an undisclosed target in a highly prevalent ophthalmic disease. ViGeneron’s vgAAVs enable the efficient transduction of target cells via intravitreal injection that allows efficient lateral spreading and minimizes th

Jan. 18, yyyy

ViGeneron signs global collaboration agreement for ophthalmic gene therapy development

Collaboration with Biogen to develop gene therapy for an undisclosed target to treat inherited eye disease, plus option for additional target
The companies will use ViGeneron’s proprietary vgAAV technology to efficiently transduce target cells via intravitreal injections

ViGeneron GmbH, a gene therapy company, today announced a global collaboration and licensing agreement with Biogen Inc. (Nasdaq: BIIB, Cambridge, Mass., USA) to develop and commercialize

Jan. 5, yyyy

ViGeneron and WuXi Advanced Therapies enter Strategic Manufacturing Partnership For Next-Generation Ophthalmic Gene Therapy

ViGeneron, a gene therapy company, and WuXi Advanced Therapies Inc. (WuXi ATU), a leading Contract, Testing, Development and Manufacturing Organization (CTDMO), today announced a strategic partnership to accelerate production for the clinical development of VG901, a next-generation ophthalmic gene therapy program.

ViGeneron’s innovative gene therapy pipeline addresses ophthalmic diseases with high unmet medical needs. Its lead product VG901 targets a disease gene for Retini

Dec. 1, yyyy